Moderna, Inc.
$234.16
▲ $7.26 (3.2%)
Day Range
$216.65 – $235.01
52W Range
$22.28 – $242.29
Volume
7,454,177
Avg Volume
19,317,784
Fundamentals are weak on several fronts. Any investment case here likely rests on a turnaround or growth story, not current business quality.
ROE of -39.0% is below the bar Buffett-style investors look for.
Operating margin of -557.9% suggests a thin-margin, competitive business.
Gross margin of -66.0% suggests limited pricing power or a commodity-like product.
SMA 20
$206.45
SMA 50
$161.77
SMA 200
$79.40
Ann. Volatility
85%
50/200-day trend
50-day average is above the 200-day average — the intermediate trend has been improving.
RSI (14)
Momentum is in a balanced range, neither overbought nor oversold.
MACD
MACD line is above its signal line, consistent with positive short-term momentum.
Bollinger Bands (20,2)
Price is trading within its normal recent volatility range.
Market Cap
$93.48B
Trailing P/E
—
Forward P/E
-52.3
PEG Ratio
—
Price / Book
13.82
Return on Equity
-39.0%
Return on Assets
-13.3%
Debt / Equity
19%
Current Ratio
2.29x
Gross Margin
-66.0%
Operating Margin
-557.9%
Net Margin
-141.4%
Revenue Growth (YoY)
+2.1%
Earnings Growth (YoY)
—
Dividend Yield
0.00%
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Debt/equity of 19% is conservative — a hallmark of resilience in downturns.
Current ratio of 2.29x means short-term obligations are well covered.
Quick ratio of 2.07x shows solid liquidity without relying on inventory.
Revenue growing 2.1% YoY is steady but unspectacular.
No earnings growth data.
No trailing P/E (often means negative earnings).
No PEG ratio available.
Price/book of 13.8x means you're paying well above net asset value.
Free cash flow is only -9% of reported net income — earnings quality worth a closer look.
Payout ratio of 0% leaves ample room to reinvest and cushion downturns.
52-week range position
Current price sits at 99% of its trailing 52-week high/low range.
Technical readings describe recent price behavior. They are not forecasts — momentum can reverse without warning.
Payout Ratio
0.0%
Beta
1.09
EPS (TTM)
-$7.98
Analyst Target (Mean)
$129.22
18 analysts
52W Range
$22.28 – $242.29